Terapeutické monoklonální protilátky v léčbě a ve vývoji

  • O. Farsa Ústav chemických léčiv, Farmaceutická fakulta, Veterinární a farmaceutická univerzita Brno, Brno
Klíčová slova: bioléčiva, terapeutické monoklonální protilátky, antineoplastika, léčiva autoimunitních nemocí, antiinfektiva, vaskulární růstové faktory, tumor nekrotizující faktor, interleukiny


This review is devoted to the therapeutic use of mo­noclonal antibodies, which are probably the most important group of biological drugs. Their classification into anti-tumour drugs, therapeutics for chronic inflammatory diseases and anti-infectives, chemical structure and nomenclature are given. The targets of the drugs, such as growth factors, microbial surface and cell wall components, various surface antigens of white blood cells, endothelial cells, tumour necrosis factor and, last but not least, interleukins and their receptors are discussed in detail. In addition to compounds authorized and used in the current treatment practice, also some important biological drugs at any stage of clinical development are presented. Finally, problems related to the formation of anti-drug antibodies in the patient organism are also mentioned.


Nejaktuálnější články stejného autora (stejných autorů)